STOCKS TELEGRAPH

Tag: VERV Stock Price

  • Verve (VERV) Stock Surges In Pre-Hour Trading Amid Lilly Buyout News

    Verve (VERV) Stock Surges In Pre-Hour Trading Amid Lilly Buyout News

    As of the most recent check, Verve Therapeutics, Inc. (NASDAQ: VERV) had a significant pre-market increase of 76.55%, reaching $11.07 per share. The disclosure that Eli Lilly and Company had reached a final agreement to purchase VERV in a deal that may be worth up to $1.3 billion has given the move speed.

    Expansion into Cardiovascular Gene Editing Strategically

    A biotechnology business in its clinical stage, Verve Therapeutics is at the forefront of gene editing treatments for atherosclerotic cardiovascular disease (ASCVD). Its cutting-edge pipeline is concentrated on creating single-administration medications that offer long-lasting and maybe permanent cardiovascular effects. The PCSK9 gene, which affects cholesterol and cardiovascular risk in general, is the target of the main candidate, VERVE-102, a first-in-class in vivo gene editing therapy.

    The U.S. Food and Drug Administration has designated VERVE-102 as Fast Track and it is presently undergoing evaluation in a Phase 1b clinical investigation. The treatment is designed for patients with early coronary artery disease and heterozygous familial hypercholesterolemia (HeFH), a hereditary disorder that affects approximately 1 in 250 persons.

    Changing the Paradigms of Cardiovascular Treatment

    With Verve’s platform, chronic maintenance may be replaced by a one-time therapeutic intervention, marking a paradigm change in cardiovascular treatment. Lilly’s strategic aim in addressing important unmet needs in cardiometabolic health is in line with the partnership. With two clinical-stage prospects created in just seven years, VERV will continue to advance its gene editing research under Lilly’s direction.

    Valuation and Deal Structure

    The agreement states that Lilly would launch a tender offer to buy all of Verve’s outstanding shares for $10.50 per share in cash, or around $1.0 billion. A contingent value right (CVR) of up to $3.00 per share will also be granted to shareholders, increasing the total possible consideration to $13.50 per share, or up to $1.3 billion overall.

    As of June 16, 2025, the offer is 113% more than Verve’s 30-day volume-weighted average stock price. Lilly will purchase any shares that remain unsold through a second-step merger once the tender offer is concluded. The board of directors of Verve has unanimously advised shareholders to accept the offer.

  • Verve Therapeutics (VERV) Shares Gain Ground In Pre-Hour Session

    Verve Therapeutics (VERV) Shares Gain Ground In Pre-Hour Session

    After a major regulatory development, Verve Therapeutics, Inc. (NASDAQ: VERV) shares enjoyed a notable surge. The news that the U.S. Food and Drug Administration (FDA) had given VERVE-102 Fast Track designation caused VERV stock to rise 8.52% to $3.31 as of the last check during pre-market trading.

    Breakthrough Therapy Addresses an Ongoing Issue

    By lowering low-density lipoprotein cholesterol (LDL-C), this experimental treatment seeks to treat individuals with hyperlipidemia and increased lifelong cardiovascular risk. A state-of-the-art in vivo base editing procedure called VERVE-102 was created to provide a one-time fix that permanently deactivates the liver’s PCSK9 gene, resulting in a sustained decrease in LDL-C.

    A Phase 1b Heart-2 clinical trial is evaluating the treatment at the moment. The purpose of this research is to evaluate safety and tolerability in adult patients with premature coronary artery disease (CAD) or heterozygous familial hypercholesterolemia (HeFH) who still need extra LDL-C reduction in spite of current treatments.

    Resolving Unmet Cardiovascular Care Needs

    Even though there are several LDL-C-lowering therapies available, about half of patients stop taking them after a year, which leaves a big hole in the long-term management of cardiovascular disease.

    Verve Therapeutics highlights the importance of long-term LDL-C decrease in changing the way atherosclerotic cardiovascular disease is treated. Being a possible single-dose treatment, VERVE-102 is in a unique position to address this persistent demand. As it moves forward with introducing this innovative strategy to patients, VERV intends to continue working closely with the FDA.

    Fast Track Status and Future Outlook

    The FDA’s Fast Track designation offers chances for rolling application assessment, more regular communication with the agency, and, if requirements are satisfied, possible Priority assessment.Future plans for Verve Therapeutics include publishing demographic, safety, and effectiveness data from the Heart-2 study in Q2 2025, delivering an opt-in package to Eli Lilly, revealing final dosage escalation findings, and starting Phase 2 studies in the second half of 2025.

  • An Uptick In Verve Stock Prompted By Promising Financials

    An Uptick In Verve Stock Prompted By Promising Financials

    Verve Therapeutics, Inc. (NASDAQ: VERV) experienced a remarkable surge of 24.83% in its stock value, closing the most recent trading session at $18.70. This notable upturn in Verve’s stock can be attributed to the release of their promising financial reports. On Tuesday, Verve (VERV) unveiled a comprehensive overview of its recent corporate advancements and financial achievements for the third quarter of 2023.

    During the third quarter of 2023, Verve (VERV) generated collaboration revenue amounting to $3.1 million. This revenue was primarily derived from research services conducted under their collaboration agreement with Vertex Pharmaceuticals Incorporated (Vertex) and the Lp(a) collaboration in conjunction with Lilly.

    In a significant stride, Verve managed to reduce its net loss, demonstrating a favorable performance for the third quarter of 2023. The net loss decreased to $45.8 million, equating to $0.72 per share, as compared to the figures of $45.2 million and $0.79 per share reported for the same period in 2022.

    In October 2023, Verve announced the expansion of its partnership with Lilly. In this development, Lilly acquired specific product rights related to Verve’s in vivo gene editing programs aimed at PCSK9, ANGPTL3, and a third undisclosed cardiovascular disease (CVD) target from Beam Therapeutics.

    This collaboration signifies Lilly’s deep expertise in the cardiometabolic field and its proficiency in commercializing products for substantial medical indications. Lilly’s substantial investment in securing Beam’s product rights further attests to its unwavering confidence in Verve’s programs and the compelling preclinical and interim clinical data supporting these initiatives.

    Gene editing, representing an exciting frontier in medical advancement, holds the potential to deliver lasting efficacy through a one-time treatment. Verve stands as a prominent leader in the development of gene editing therapies tailored to combat cardiovascular diseases.

    Verve and Lilly started a partnership in June 2023 establishing an exclusive research collaboration. The primary focus of that was on advancing Verve’s preclinical in vivo gene editing program, directed at addressing lipoprotein(a) (Lp(a)). This partnership underscores the strategic synergy between the two entities in advancing cutting-edge medical solutions.